These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23463744)

  • 1. Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
    Perelman M; Leake S
    Ann Pharmacother; 2013 Mar; 47(3):428. PubMed ID: 23463744
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
    Grassin-Delyle S; Naline E; Devillier P
    Ann Pharmacother; 2013 Mar; 47(3):427-8. PubMed ID: 23463741
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment: intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain. Authors' reply.
    Dietrich E; Gums JG
    Ann Pharmacother; 2013 Mar; 47(3):429. PubMed ID: 23463745
    [No Abstract]   [Full Text] [Related]  

  • 4. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
    Dietrich E; Gums JG
    Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fentanyl pectin nasal spray for breakthrough cancer pain.
    Torres LM; Trinidad JM; Calderón E; Benitez D; Perelman M
    Int J Palliat Nurs; 2015 Mar; 21(3):114-6. PubMed ID: 25815759
    [No Abstract]   [Full Text] [Related]  

  • 6. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain.
    Thronæs M; Popper L; Eeg M; Jaatun E; Kvitberg M; Kaasa S
    Clin Ther; 2015 Mar; 37(3):585-96. PubMed ID: 25641199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to the use of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care: an exploratory survey.
    Harrop E; Jamieson L; Choy TH; Ho WHP; Wong ICK
    BMJ Support Palliat Care; 2018 Sep; 8(3):355-356. PubMed ID: 28801316
    [No Abstract]   [Full Text] [Related]  

  • 9. Fast-acting fentanyl preparations and pain management.
    McWilliams K; Fallon M
    QJM; 2013 Oct; 106(10):887-90. PubMed ID: 23613597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient satisfaction with intranasal fentanyl for breakthrough pain.
    Veldhorst-Janssen NM; Fiddelers AA; Zandstra H; Kessels AG; Zandstra H; Marcus MA; Neef C; van der Kuy PH
    J Palliat Med; 2012 Jun; 15(6):631-2. PubMed ID: 22656053
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Gombert-Handoko KB
    Clin Ther; 2014 Nov; 36(11):1704. PubMed ID: 25048312
    [No Abstract]   [Full Text] [Related]  

  • 12. Fentanyl buccal film. New oral transmucosal form has no advantages in breakthrough pain.
    Prescrire Int; 2013 Oct; 22(142):237. PubMed ID: 24298583
    [No Abstract]   [Full Text] [Related]  

  • 13. Are there cost benefits to fentanyl for breakthrough pain?
    Davis MP
    J Pain Symptom Manage; 2012 Sep; 44(3):e1-2. PubMed ID: 22939453
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of oral formulations of fentanyl for breakthrough cancer pain.
    Handsaker S; Dempsey L; Fabby C
    Int J Palliat Nurs; 2015 Apr; 21(4):168, 170-2. PubMed ID: 25901588
    [No Abstract]   [Full Text] [Related]  

  • 15. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fentanyl pectin nasal spray for breakthrough cancer pain.
    Taylor DR; Gabrail N
    Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD004311. PubMed ID: 26275024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
    Kaessner N; Nave R; Roepcke S; Facius A; Lahu G
    Int J Clin Pharmacol Ther; 2012 Sep; 50(9):665-77. PubMed ID: 22784611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.